CAS |
No.319460-85-0 |
中文名称 |
阿西替尼(10mM in DMSO,无菌) |
英文名称 |
Axitinib(10mM in DMSO,Sterile) |
分子式 |
C22H18N4OS |
分子量 |
386.47 |
溶解性 |
请根据自己的实验要求使用。 |
外观(性状) |
无菌溶液 |
储存条件 |
Stroe at -20℃,6 months. |
靶点 |
VEGFR |
通路 |
Angiogenesis;Protein Tyrosine Kinase/RTK |
背景说明 |
Axitinib是多靶点的酪氨酸激酶抑制剂,抑制 VEGFR1,VEGFR2,VEGFR3, PDGFRβ 。 |
生物活性 |
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.[1-3] |
In Vitro |
Axitinib (AG-013736) 是一种有效的选择性 VEGFR 1 至 3 抑制剂。在转染或内源性 RTK 表达细胞中,Axitinib 有效阻断生长因子刺激的 VEGFR-2 和 VEGFR-3 磷酸化,平均 IC50 值分别为 0.2 和 0.1 至 0.3 nM。基于 Axitinib 的蛋白结合,针对 VEGFR-1 的细胞活性为 1.2 nM (在存在 2.3% 牛血清白蛋白的情况下测量),相当于绝对 IC50 ~0.1 nM。在 Flk-1 转染的 NIH-3T3 细胞中针对鼠 VEGFR-2 (Flk-1) 的效力为 0.18 nM,与其人类同系物相似。Axitinib 对密切相关的 III 型和 V 型家族 RTK,包括 PDGFR-β (1.6 nM)、KIT (1.7 nM) 和 PDGFR-α,显示出约 8 至 25 倍的 IC50 (5 nM);纳摩尔浓度的 Axitinib 可阻断 PDGF BB 介导的人神经胶质瘤 U87MG 细胞 (PDGFR-β 阳性) 迁移,但不会阻断增殖[2]。 |
In Vivo |
与对照肿瘤相比,单次口服剂量的 Axitinib (100 mg/kg) 显著抑制小鼠 VEGFR-2 磷酸化长达 7 小时。Axitinib 快速抑制 VEGF 诱导的小鼠皮肤血管通透性;这种抑制是剂量依赖性的,并且与小鼠体内的药物浓度直接相关。药代动力学/药效学分析表明未结合的 EC50 为 0.46 nM。在没有外源性 VEGF-A 刺激的 MV522 荷瘤小鼠的皮肤中也显示出类似的抑制作用。Axitinib 抑制小鼠人异种移植肿瘤的生长。无论初始肿瘤大小、模型类型或植入部位如何,阿西替尼都会产生剂量依赖性生长延迟[2]。 |
细胞实验 |
Endothelial or tumor cells are starved for 18 h in the presence of either 1% FBS (HUVEC) or 0.1% FBS (tumor cells). Axitinib is added and cells are incubated for 45 min at 37°C in the presence of 1 mM Na3VO4. The appropriate growth factor is added to the cells, and after 5 min, cells are rinsed with cold PBS and lysed in the lysis buffer and a protease inhibitor cocktail. The lysates are incubated with immunoprecipitation antibodies for the intended proteins overnight at 4°C. Antibody complexes are conjugated to protein A beads and supernatants are separated by SDS-PAGE[2]. |
动物实验 |
Mice and Rats[2] Mice with M24met xenograft tumors (400-600 mm3) are administered with a single dose of Axitinib or the control (0.5% carboxymethylcellulose/H2O). Blood and tumor tissue samples are collected for pharmacokinetic and VEGFR-2 measurements. Total protein concentrations in tumor tissues are determined using the Bradford colorimetric assay. Six-day-old Sprague-Dawley rats are given two i.p. injections of Axitinib (30 mg/kg ). Animals are sacrificed, retinas are collected and lysed, and immunoprecipitation/immunoblotting experiments are done. ECL-Plus is used for detection and densitometry analysis is done using the Alpha Imager 8800. |
数据来源文献 |
[1]. Fenton BM, et al. The addition of AG-013736 to rractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67(20):9921-8. [2]. Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272-83 [3]. Allen E, et al. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep. 2016 May 10;15(6):1144-60. |
规格 |
1ml |
单位 |
瓶 |